Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;40(6):1513-1522.
doi: 10.1007/s00345-022-03997-2. Epub 2022 May 2.

Global experience and progress in GreenLight-XPS 180-Watt photoselective vaporization of the prostate

Affiliations

Global experience and progress in GreenLight-XPS 180-Watt photoselective vaporization of the prostate

Isabel Lichy et al. World J Urol. 2022 Jun.

Abstract

Purpose: To evaluate changes in global perioperative data of GreenLight-XPS 180-Watt photo-selective vaporization of the prostate (GL-XPS) of the Global Greenlight Group (GGG) database.

Methods: 3441 men, who underwent GL-XPS for symptomatic BPH between 2011 and 2019 at seven high volume international centers, were included. Primary outcome measurements were operative time (OT; min), effective laser time (LT; min of OT), as well as intraoperative and postoperative adverse events (AEs), all analyzed by year of surgery (2011-2019) and prostate volume (PV) group (< 80 ml vs. 80-150 ml vs. > 150 ml).

Results: The median age was 70 years (interquartile range 64-77), the median PV was 64 ml (IQR 47-90). The OT and LT slightly increased but stayed highly efficient all in all. Median OT was 60 min (IQR 45-83) and LT was 33 min (IQR 23-46). Median energy use was 253 kJ (IQR 170-375) with an energy density of 3.94 kJ/ml (IQR 2.94-5.02). The relative probability of perioperative AEs decreased by 17% each year (p < 0.001). The relative probability of perioperative transfusion dropped significantly from 2% in 2011 to 0% in 2019 (p = 0.007). The early postoperative complications (within 30 days after surgery) decreased significantly from 48.8% (n = 106) in 2011 to 24.7% (n = 20) in 2019 (p > 0.001).

Conclusion: These findings from the GGG demonstrate significant improvement secondary to growing experience with GL-XPS between 2011 and 2019 in intraoperative AEs, including transfusions, and postoperative AEs. While staying highly efficient in OT and LT of GL-XPS within a 9-year period of experience.

Keywords: BPH; GL-XPS; Global Greenlight Group; Global experience; Greenlight.

PubMed Disclaimer

Conflict of interest statement

Hannes Cash, Kevin Zorn, Dean Elterman, Edgardo F. Becher, Giovanni Ferrari and Luca Cindolo report receiving honoraria as consultant/proctor for Boston Scientific. All other authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
Clinical research flowchart
Fig. 2
Fig. 2
Significant parameters of intraoperative baseline results between 2011 and 2019 in correlation to prostate volume group 1–3, a OT, b LT, c LT/OT ratio, d LT/TRUS volume, e Energy/LT, f Energy used, g complications, perioperative
Fig. 3
Fig. 3
Early postoperative complications (< 30 days) between 2011 and 2019 in correlation to prostate volume group 1–3

References

    1. Foster HE, Barry MJ, Dahm P et al (2018) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol 200(3):612–619. https://www.ncbi.nlm.nih.gov/pubmed/29775639 - PubMed
    1. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109. doi: 10.1016/j.eururo.2014.12.038. - DOI - PubMed
    1. Valdivieso R, Hueber PA, Meskawi M et al (2018) Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int 122(5):873–878. https://www.ncbi.nlm.nih.gov/pubmed/29570929 - PubMed
    1. Stone BV, Chughtai B, Forde JC et al (2016) Safety and Efficacy of GreenLight XPS laser vapoenucleation in prostates measuring over 150 mL. J Endourol 30(8):906–912. https://www.ncbi.nlm.nih.gov/pubmed/27203515 - PubMed
    1. Nickel JC, Aaron L, Barkin J et al (2018) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 12(10):303–312. https://www.ncbi.nlm.nih.gov/pubmed/30332601 - PMC - PubMed